Two Massachusetts biotech firms shut down operations amid funding challenges
Adecto Pharmaceuticals has ceased operations after exhausting its financial resources in a restrictive fundraising environment, according to CEO Nora Minerva. The company had been developing an immunotherapy treatment for cancers resistant to conventional approaches and filed a provisional patent to preserve its work. Separately, Aviceda Therapeutics is winding down following disappointing Phase 2b clinical trial results for its retinal disease therapy.
Adecto's shutdown reflects the current difficult financing landscape for early-stage biotech companies pursuing novel approaches. Founded by Tufts researchers in 2014, the company had secured government grants including a $2 million Phase 2 award from the National Cancer Institute, yet these resources proved insufficient to advance its immunotherapy platform to clinical testing. Its ADAM8-targeting approach represents a category of research that requires substantial capital before generating human trial data—precisely the type of investment institutional funders have become reluctant to support during market downturns.
Aviceda's closure stems from a different challenge: the company completed Phase 2b testing but failed to demonstrate clear superiority over existing treatments. While the retinal disease therapy showed safety and some clinical benefit, the lack of a statistically significant primary endpoint outcome essentially eliminated the path to regulatory approval and subsequent funding for the expensive Phase 3 trials the company had planned.
These closures illustrate dual obstacles facing biotech innovation: insufficient capital for unproven therapeutic approaches and clinical trial disappointments that eliminate investment opportunities. Patient populations targeted by both companies—those with therapy-resistant cancers and advanced macular degeneration—may see delayed access to potential alternative treatments. The losses could also signal broader contraction in venture funding for life sciences, potentially affecting recruitment and development timelines across the sector as talented researchers seek stability elsewhere.